This PopPK model accurately estimated GBP concentrations in patients with neuropathic pain, using eGFR as a covariate for total clearance. The distribution and excretion processes of GBP were not affected by hyperglycaemia or diabetes (British Journal of Clinical Pharmacology)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
Efficacy, renal safety and tolerability of SGLT2i were similar in people >70 compared to 65–70 years of age, suggesting that a wider use should not be worried even in the elderly. However, some caution must be paid to the occurrence of persistent eGFR decline and orthostatic hypotension, especially in patients >70 years old (Primary Care Diabetes)
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial
FMT halts decline in endogenous insulin production in recently diagnosed patients with T1D in 12 months after disease onset. Several microbiota-derived plasma metabolites and bacterial strains were linked to preserved residual beta cell function. This study provides insight into the role of the intestinal gut microbiome in T1D(BMC Gut)
The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes
Lifetime risk of autoimmune disease in longstanding T1D approaches 50%, is greater in females, and is driven by thyroid disease. The probability of diabetes complications such as CVD was lower in those with autoimmune disease, which was driven mostly by non-thyroid autoimmune diseases (Canadian Journal of Diabetes)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (NEJM)
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines (Cardiovascular Diabetology)
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, and low-dose ATG ± granulocyte-colony–stimulating factor trials in an attempt to rank the effectiveness of the agents studied. C-peptide 2-h area under the curve means were modeled using analysis of covariance (Diabetes Technology and Therapeutics)
Neutrophil count as a reliable marker for diabetic kidney disease in autoimmune diabetes
Neutrophil counts are closely associated with DKD in patients with autoimmune diabetes, suggesting that neutrophil-mediated inflammation may be involved in the pathogenesis of DKD in patients with autoimmune diabetes (BMC Endocrine Disorders)
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
This review suggests that there is a significantly lower risk of incident AF for individuals on SGLT2 inhibitors versus placebo (Diabetes, Obesity and Metabolism)
Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus
Periodical dosing of vitamin B12 should be performed in the case of patients with Type 2 Diabetes Mellitus treated with metformin, especially if they associate anemia and/or peripheral diabetic polyneuropathy (Diabetes, Metabolic Syndrome and Obesity)
Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study
In a cohort of hypertensive patients who had DM but no history of cardiovascular disease, lower BP was associated with lower risk of cardiovascular events especially at the age of < 70. However, low BP < 130–139/80–89 mmHg was not associated with decreased cardiovascular risk, it may be better to keep the BP of 130–139/80–89 mmHg at the age of ≥ 70 (Cardiovascular Diabetology)
Sustained Impact of Real-Time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study
Use of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, less acute hypoglycemia-related events, and diabetes-related days off from work were observed, particularly in those with IAH (Diabetes Care)
Adaptation of Insulin Clearance to Metabolic Demand is a Key Determinant of Glucose Tolerance
The development of IR in obese subjects is associated with decline in MCRI that represents a compensatory response to maintain normal glucose tolerance but is impaired in T2DM individuals (Diabetes)
Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study
High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high plasma concentrations of copeptin were associated with an increased risk of incident prediabetes/T2D (Cardiovascular Diabetology)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
In patients with T2DM with or without baseline HF, ertugliflozin reduced risk for first and total HHF and total HHF/CV death, adding further support for the use of SGLT2 inhibitors in primary and secondary prevention of HHF (Circulation)
Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes
Position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (Diabetologia)
SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes
Treatment with SGLT2 inhibitors results in clear and consistent reductions in cardiovascular, kidney and mortality outcomes regardless of whether patients are receiving or not receiving metformin (Diabetes, Obesity and Metabolism)
Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
The potential benefits of sustained and continuous disease control that early combination therapy offers represent the start of a new era in early diagnosis and intensive management, to achieve the treatment aims of type 2 diabetes (Diabetes Therapy)
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
SGLT-2 inhibitors are the latest class of therapies to demonstrate important clinical benefits among patients with HFrEF, and their pharmacological properties favor ease of use and integration in multi-drug disease-modifying regimens (Current Cardiology Reports)
Metformin use in prediabetes: is earlier intervention better?
The largest reductions in both incidence of diabetes and FPG occurred in prediabetic persons with a higher level of FPG at baseline. Metformin was able to stabilise insulin sensitivity and was more effective in persons with more pronounced IFG (Acta Diabetologica)
- 1
- 2
- 3
- …
- 205
- Next Page »
Glycosmedia is also available as an App: